Diagnosis and therapy of autoimmune liver disease (Q41109690)

26 September 2017

1 reference

title

Diagnosis and therapy of autoimmune liver disease (English)

1 reference

26 September 2017

Czaja AJ

1

1 reference

PubMed ID

8804371

26 September 2017

language of work or name

1 reference

1 September 1996

1 reference

Medical Clinics of North America

26 September 2017

1 reference

26 September 2017

80

1 reference

26 September 2017

5

1 reference

26 September 2017

973-994

1 reference

Characterization of the liver cytosol antigen type 1 reacting with autoantibodies in chronic active hepatitis

26 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970476-4

Autoimmune chronic active hepatitis masquerading as acute hepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970476-4

The histological features of chronic hepatitis C and autoimmune chronic hepatitis: a comparative analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970476-4

Ursodeoxycholic acid therapy in chronic active hepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970476-4

The problem of chronic liver disease in young women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970476-4

Seroprevalence of hepatitis C virus nucleocapsid antibodies in patients with cryptogenic chronic liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970476-4

Recent-onset autoimmune hepatitis. Biopsy findings and clinical correlations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970476-4

Controlled Prospective Trial of Corticosteroid Therapy in Active Chronic Hepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970476-4

The prognosis of chronic active hepatitis without cirrhosis in relation to bridging necrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970476-4

'Acute' autoimmune hepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970476-4

Auto-immune chronic active hepatitis: a specific entity? The negative argument

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970476-4

Autoimmune hepatitis. Evolving concepts and treatment strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970476-4

Chronic active hepatitis: the challenge for a new nomenclature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970476-4

Low-dose corticosteroid therapy after multiple relapses of severe HBsAg-negative chronic active hepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970476-4

Natural history, clinical features, and treatment of autoimmune hepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970476-4

Sustained remission after corticosteroid therapy of severe hepatitis B surface antigen-negative chronic active hepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970476-4

Sensitivity, specificity, and predictability of biopsy interpretations in chronic hepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970476-4

Antibodies to soluble liver antigen, P450IID6, and mitochondrial complexes in chronic hepatitis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970476-4

Evidence against hepatitis viruses as important causes of severe autoimmune hepatitis in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970476-4

Genetic predispositions for the immunological features of chronic active hepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970476-4

The nature and prognosis of severe cryptogenic chronic active hepatitis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970476-4

Complete resolution of inflammatory activity following corticosteroid treatment of HBsAg-negative chronic active hepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970476-4

Clinical features and prognostic implications of severe corticosteroid-treated cryptogenic chronic active hepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970476-4

Corticosteroid-treated chronic active hepatitis in remission: uncertain prognosis of chronic persistent hepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970476-4

Hepatitis C virus infection as a determinant of behavior in type 1 autoimmune hepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970476-4

Frequency and significance of antibodies to liver/kidney microsome type 1 in adults with chronic active hepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970476-4

Features reflective of early prognosis in corticosteroid-treated severe autoimmune chronic active hepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970476-4

Frequency and significance of antibody to hepatitis C virus in severe corticosteroid-treated autoimmune chronic active hepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970476-4

Long-term follow-up of chronic active hepatitis of moderate severity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970476-4

Cirrhosis of undefined pathogenesis: absence of evidence for unknown viruses or autoimmune processes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970476-4

Anti-liver kidney microsome antibody recognizes a cytochrome P450 from the IID subfamily

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970476-4

Controlled trial of a thymic hormone extract (Thymostimulin) in 'autoimmune' chronic active hepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970476-4

Relapse following treatment withdrawal in patients with autoimmune chronic active hepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970476-4

Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: a second type of "autoimmune" hepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970476-4

Prevalence of antibodies to hepatitis C virus among patients with cryptogenic chronic hepatitis and cirrhosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970476-4

Use of polyunsaturated phosphatidyl choline in HBsAg negative chronic active hepatitis: results of prospective double-blind controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970476-4

Meeting report: International Autoimmune Hepatitis Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970476-4

Chronic lobular hepatitis: a clinicopathological and prognostic study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970476-4

Cytochromes P-450 in human hepatocyte plasma membrane: recognition by several autoantibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970476-4

Clonal analysis of liver-infiltrating T cells in patients with LKM-1 antibody-positive autoimmune chronic active hepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970476-4

Subdivisions of idiopathic autoimmune chronic active hepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970476-4

Characterisation of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970476-4

Patients with type II autoimmune hepatitis express functionally intact cytochrome P-450 db1 that is inhibited by LKM-1 autoantibodies in vitro but not in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970476-4

LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P-450 monooxygenase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970476-4

Major antigen of liver kidney microsomal autoantibodies in idiopathic autoimmune hepatitis is cytochrome P450db1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970476-4

Antibody to liver cytosol (anti-LC1) in patients with autoimmune chronic active hepatitis type 2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970476-4

Antibodies to liver-specific protein predict outcome of treatment withdrawal in autoimmune chronic active hepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970476-4

Hepatitis C virus antibodies in chronic active hepatitis: pathogenetic factor or false-positive result?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970476-4

Arginine Thiazolidinecarboxylate in the Treatment of Chronic Active Hepatitis: Double-Blind Comparison with Placebo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970476-4

Controlled trial of prednisone and azathioprine in active chronic hepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970476-4

Effect of polyunsaturated phosphatidylcholine on immune mediated hepatocyte damage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970476-4

Recurrence of autoimmune chronic active hepatitis following orthotopic liver grafting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970476-4

The nature and prognostic implications of autoimmune hepatitis with an acute presentation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970476-4

Frequency and significance of chronic ulcerative colitis in severe corticosteroid-treated autoimmune hepatitis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970476-4

The Vocabulary of Chronic Hepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970476-4

The asialoglycoprotein receptor as target structure in autoimmune liver diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970476-4

Anti-liver-kidney microsome antibody-positive autoimmune hepatitis presenting as fulminant liver failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970476-4

Simultaneous occurrence of primary sclerosing cholangitis and autoimmune chronic active hepatitis in a patient with ulcerative colitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970476-4

Prognostic features and role of liver transplantation in severe corticosteroid-treated autoimmune chronic active hepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970476-4

Severe chronic active liver disease. Prognostic significance of initial morphologic patterns

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970476-4

Drug-induced chronic liver disease, with emphasis on chronic active hepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970476-4

Characterization and clinical relevance of liver-pancreas antibodies in autoimmune hepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970476-4

Maintenance of remission in autoimmune chronic active hepatitis with azathioprine after corticosteroid withdrawal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970476-4

Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970476-4

FK 506: a novel immunosuppressant for treatment of autoimmune disease. Rationale and preliminary clinical experience at the University of Pittsburgh

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970476-4

Regulation of cytochrome P450 IID by acute phase mediators in C3H/HeJ mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970476-4

Characterization of liver cytokeratin as a major target antigen of anti-SLA antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970476-4

Extrahepatic malignancy following long-term immunosuppressive therapy of severe hepatitis B surface antigen-negative chronic active hepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970476-4

Disease recurrence and rejection following liver transplantation for autoimmune chronic active liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970476-4

Characterization of anti-liver-kidney microsome antibody (anti-LKM1) from hepatitis C virus-positive and -negative sera.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970476-4

Antibodies against human cytochrome P-450db1 in autoimmune hepatitis type II.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970476-4

Duration and specificity of antibodies to hepatitis C virus in chronic active hepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970476-4

inferred from DOI database lookup

7 January 2021

based on heuristic

Oral budesonide for treatment of autoimmune chronic active hepatitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970476-4

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0025-7125(05)70476-4

1 reference

26 September 2017

1 reference

PubMed ID

8804371